

Interventional Oncology (IO) Sub-committee

The aim of the IO Sub-committee is to advance the practise of interventional oncology within Australia and New Zealand.

Work plan – 2021

Objective/Aim (link to ToR)	Details of the task/Initiative	Assigned to	Due date	Status
1. Formation of an IO Special Interest Group (SIG)	<ul style="list-style-type: none"> ● Changes to IRSA constitution needed at the 2021 AGM <ul style="list-style-type: none"> ○ Develop ToR for a SIG, including identifying suitable membership, aims and objectives of the SIG ○ Discuss the introduction of a fee for SIG membership (IRSA members V non-IRSA members) ○ Incorporation of Non-IR's to the SIG to expand its influence and relevance within clinical oncology 	All	01 May 2021	
2. Advocacy and promotion of IO	<ul style="list-style-type: none"> ● Definition of interventional oncology <ul style="list-style-type: none"> ○ sub-specialty of Interventional Radiology ○ What IO is? ○ What an IO does? ○ Value of IO? <ul style="list-style-type: none"> ▪ to patients/community ▪ to hospitals/health systems ▪ to governments ● Develop a Range of Practice and Scope of Practice for IO in Australia and New Zealand <ul style="list-style-type: none"> ○ Recommend collaboration with IRC/IRTPWG via Gerard Goh 			

	<ul style="list-style-type: none"> ● Review of RANZCR’s Interventional Radiology Standards of Practise from an IO perspective ● Review the (CIRSE’s) IASIOS Quality Standards and assess for suitability for ANZ context <ul style="list-style-type: none"> ○ Investigate feasibility of endorsement ● Ensure meaningful engagement with RANZCR and harmonisation of strategies to promote IO and IR. 			
<p>3. Optimise engagement with TROG to promote IO research</p>	<ul style="list-style-type: none"> ● Build links with TROG <ul style="list-style-type: none"> ○ Strategise for the best ways to leverage IR’s relationships with TROG to maximise IO research opportunities and potential ● Promote affiliate TROG IO membership to IRSA members <ul style="list-style-type: none"> ○ IRSA Executive to circulate a communique to IRSA members promoting free TROG affiliate membership ● Engagement with senior TROG specialists to discuss collaborative opportunities, including – <ul style="list-style-type: none"> ○ SMART workshops and Concept development workshops for Junior members, emerging researchers and other interested members, held in conjunction with the TROG ASM ○ Statistics, funding and patient-centred concepts ○ Promote research project ideas and collaboration to solve research problems ● Ensure that IO, and in particular IO research outcomes, are widely promotes and integrated into clinical care 			

	<ul style="list-style-type: none"> ○ work with TROG to promote the efficacy and value of IO care 			
4. Increase emphasis on IO research outcomes and published literature	<ul style="list-style-type: none"> ● Promote collaboration amongst IR departments and sites <ul style="list-style-type: none"> ○ Encourage the formation of research networks ○ Run workshops with live cases ○ Education and research sessions ○ Sharing research/collaborating on research ideas ● Ensure positive IO research outcomes are translated into clinical practise <ul style="list-style-type: none"> ○ Promoting MDT awareness ○ Inclusion in clinical guidelines and treatment algorithms ● Optimise collaborative research with other oncology research organisations, eg TROG, COSA, CIRSE, SIO 			
5. IO Clinical Symposium 2021	<ul style="list-style-type: none"> ● Investigate the feasibility of holding the IO Clinical Symposium in conjunction with the 2021 IRSA ASM – <ul style="list-style-type: none"> ○ Build on original Symposium objectives of promoting <i>Clinical</i> aspects of IO, rather than <i>Technical</i>. Items could include – <ul style="list-style-type: none"> ▪ Lectures on managing cancers from Med Onc, Surgeon and Rad Onc perspectives ▪ Clinical skills and language, eg how to undertake a consultation (what constitutes a consult, patient awareness, manner, appropriate language) ▪ How IO can and should fit into the Oncology Team ▪ Strategies for effective MDTs 	All; NB convenor	Discuss in early Jan 2021	

	<ul style="list-style-type: none"> ▪ Tools to educate IR's on immunology (understanding the correct language to include in reports) ● Consider future expansion opportunities and potential to evolve into a stand-alone Australasian / Asia-Pacific IO Conference 			
<p>6. Build international affiliate relationships as part of increasing Educational opportunities for IO's</p> <p>Aim: Advocacy, Education</p>	<ul style="list-style-type: none"> ● Build links with SIO, ECIO and CIRSE <ul style="list-style-type: none"> ○ Sharing resources ○ International affiliation opportunities for members 			
<p>7. Clinical Guidelines review, oversight and development</p> <p>Aim: Advocacy</p>	<ul style="list-style-type: none"> ● Review GESA Consensus Statement on HCC ● Contribute to finalisation of Renal Ablation Guidelines ● Development of other Clinical guidelines for IO procedures <ul style="list-style-type: none"> ○ Audit existing international clinical guidelines for IO procedures 			